Risa Takayanagi

Tokyo, 1920392, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Effects of olopatadine hydrochloride on substance P concentrations in nasal secretions and nasal symptoms.

Effects of olopatadine hydrochloride on substance P concentrations in nasal secretions and nasal symptoms.

Journal: World journal of experimental medicine

Published: November 17, 2025

OPTIMAL PLASMA CONCENTRATION OF THROMBOMODULIN ALFA TO TREAT SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION.

OPTIMAL PLASMA CONCENTRATION OF THROMBOMODULIN ALFA TO TREAT SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION.

Journal: Shock (Augusta, Ga.)

Published: June 21, 2023

Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling.

Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: December 21, 2019

Therapeutic and Adverse Effects of Thrombomodulin Alfa to Treat Sepsis-Induced Disseminated Intravascular Coagulation.

Therapeutic and Adverse Effects of Thrombomodulin Alfa to Treat Sepsis-Induced Disseminated Intravascular Coagulation.

Journal: Shock (Augusta, Ga.)

Published: November 26, 2019

Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling.

Prediction of clinical effects of infliximab administered for inflammatory bowel disease based on pharmacokinetic and pharmacodynamic modeling.

Journal: Biopharmaceutics & drug disposition

Published: January 16, 2019

Comparisons of Usual Dose of Pharmaceutical Products Used in Japan and United States: Can Differences Be Explained by Pharmacokinetics Alone?

Comparisons of Usual Dose of Pharmaceutical Products Used in Japan and United States: Can Differences Be Explained by Pharmacokinetics Alone?

Journal: Therapeutic innovation & regulatory science

Published: November 02, 2018

Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.

Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.

Journal: Biological & pharmaceutical bulletin

Published: February 02, 2018

Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease.

Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease.

Journal: Biopharmaceutics & drug disposition

Published: December 27, 2017

Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment.

Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment.

Journal: Medical oncology (Northwood, London, England)

Published: August 29, 2017

Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.

Analysis of Clinical Efficacy and Adverse Effects of β-Blocking Agents Used Clinically for Chronic Heart Failure.

Journal: Biological & pharmaceutical bulletin

Published: June 02, 2017

Study of Safety Evaluation in Dispensing of Medicines-Analysis of Relationship between Dispensing Error Rate, Inspecting Error Rate, and Malpractice Rate.

Study of Safety Evaluation in Dispensing of Medicines-Analysis of Relationship between Dispensing Error Rate, Inspecting Error Rate, and Malpractice Rate.

Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

Published: May 02, 2017

Effects of FCGRIIIa-158V/F polymorphism on antibody-dependent cellular cytotoxicity activity of adalimumab.

Effects of FCGRIIIa-158V/F polymorphism on antibody-dependent cellular cytotoxicity activity of adalimumab.

Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica

Published: March 03, 2017

Showing 1-12 of 34

Last Updated: 09/26/2026